Alpha Cognition Inc
ACOG
NASDAQ·Healthcare·Biotechnology·Mkt cap $147.9M
$9.52
▲ +3.37%
P/E
-10.60
Mkt Cap
$147.9M
52-Wk Range
$4.50–$10.14
52-Week Range
$4.50 - $10.14
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 0.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary drug formulations targeting underserved neurological markets
- Diversified pipeline across multiple neurodegenerative disease indications
- Clinical stage advancement reducing early-stage development risk
- Novel gene therapy approach to ALS treatment
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Clinical trial progression and regulatory approvals for pipeline candidates
Value
Deep value opportunity - significant discount to Digital Payments peers
Momentum
Hot
+58.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ACOG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.40 vs -$0.39 consensus (-2.0% surprise). Revenue of $6.0M vs $4.4M expected (+36.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.0%
Revenue trend · last 8Q
—
—
—
—
—
—
+21%
+268%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$2.1M
$1.2M
$2.0M
$2.0M
$2.5M
$6.1M
Margins · last 8Q
Gross
93.6%
Operating
-127.3%
Profit
0.0%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 20, 2026
vs Industry
How ACOG stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related